ISSN: 3049-3277

International Journal of Integrative Studies (IJIS)

Journal homepage: www.ijis.co.in

RESEARCH ARTICLE

Oropouche Virus Disease: A Conceptual and Theoretical Review of Virology, Vector Biology, Pathogenesis, Clinical Features, and Exploratory Therapeutics

[1]*Mahammad Zaid Md Atik, [2]Vyankatesh.S.Lakde, [3]Dr. Rahul S Bijwar

[*1]Pharma Researcher Student, Jagadambha Institute of Pharmacy and Research. mahammadzaid31@gmail.com
[2]Assistant Professor, Jagadambha Institute Of Pharmacy And Research Kalamb. lakdevyankatesh@gmail.com
[3]Principal, Jagadambha Institute of Pharmacy And Research

ABSTRACT

During our Bachelor of Pharmacy coursework, we spend a lot of time studying common infectious diseases like malaria, dengue, and typhoid. We rarely hear about Oropouche virus (OROV) unless we look into neglected tropical fevers. This paper is a purely conceptual and theoretical literature review prepared from a pharmacy student perspective, and we do not make any clinical, experimental, or therapeutic claims anywhere in this document. Based on published scientific reports, OROV is described as an enveloped, negative-sense RNA virus with three separate genetic segments (Large, Medium, and Small) that belongs to the Orthobunyavirus group [1, 4, 15]. Unlike dengue, which relies on urban mosquitoes, OROV is mainly passed between people by tiny biting midges known as Culicoides paraensis, while staying alive quietly in wild forest animals like sloths and monkeys [2, 6]. People who catch the fever usually get a sudden high temperature, strong pain behind the eyes, muscle aches, and sickness. One unusual thing often mentioned in clinical papers is that the fever seems to go away after four or five days, but then comes back a few days later in almost half of the patients [2, 10]. Recent health reports from 2023 and 2024 in South America and the Caribbean also raised questions about possible brain irritation and mother-to-child transmission during pregnancy [7, 8, 17]. Right now, there is no approved antiviral medicine or vaccine for Oropouche fever [9]. Care is only supportive, mostly using simple fluids and paracetamol for fever, while avoiding aspirin or NSAIDs like ibuprofen because of bleeding concerns if dengue is also suspected. In this conceptual review, we look at how the virus is built, how midges breed in rotting farm waste, how laboratory testing works across early and late fever windows, and how basic medicinal chemistry ideas might apply in theory to viral enzymes like the RNA polymerase, without claiming that any drug or vaccine actually works in patients today.

Keywords: *Oropouche virus, Conceptual review, Culicoides paraensis, Orthobunyavirus, Theoretical drug targets, B. Pharm literature study*

INTRODUCTION

1.1 How the Virus Was First Found and Named

When we read about viral fevers in tropical countries, dengue and chikungunya usually take up almost every chapter in our textbooks. Oropouche virus (OROV) is much less famous, even though it has been making people sick across South America for a very long time. Taxonomically, scientists place OROV inside the genus Orthobunyavirus and the family Peribunyaviridae [4, 15]. It is a small RNA virus whose genetic material is split into three pieces. Before going further, it is important to say clearly that this review is strictly a conceptual academic summary—we are not claiming any new medical facts or treatment rules here.

Pharma/Researcher Student, Jagadambha Institute of Pharmacy and Research
Email-id: mahammadzaid31@gmail.com

Corresponding Author: Mahammad Zaid Md Atik
Pharma/Researcher Student, Jagadambha Institute of Pharmacy And Research
DOI: https://doi.org/10.63856/ijis/v2i11/03

How to cite this article: Atik, M. Z. M., (2026). Oropouche Virus Disease: A Conceptual and Theoretical Review of Virology, Vector Biology, Pathogenesis, Clinical Features, and Exploratory Therapeutics. *International Journal of Integrative Studies*, 2(11), 22-34.

Source of support: Nil
Conflict of interest: None.
Received: 05/11/2026 **Revised:** 10/11/2026 **Accepted:** 15/11/2026 **Published:** 26/11/2026

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited

The history of this virus goes back to September 1955 on the island of Trinidad. A 24-year-old man who worked in the forest near a village called Vega de Oropouche came down with a sudden high fever, bad headache, and backache [1]. Doctors at the Trinidad Regional Virus Laboratory took a blood sample from him and grew a virus that nobody had seen before. Not long after that patient recovered, field workers caught forest mosquitoes (Coquillettidia venezuelensis) in the nearby Melajo woods and found the same virus inside them [1]. That early finding suggested right away that biting insects were carrying the virus from the forest to people working nearby.

A few years later, around 1960, researchers in Brazil were studying fevers along the new road being built between Belém and Brasília. They found the virus in the blood of a wild three-toed sloth (Bradypus tridactylus) [2]. That discovery gave scientists the idea that the virus lives naturally in jungle animals without necessarily making them look sick, and that people mostly run into it when trees are cut down for roads or farms. Back in the 1960s and 1970s, most small Amazon clinics did not have virus labs, so local health workers often called these sudden fevers 'summer fever' or assumed they were mild malaria or dengue [2, 3].

1.2 Recent Outbreaks Reported in 2023 and 2024

For decades, most medical writers treated Oropouche fever as a rough but temporary illness that stayed mostly inside the Amazon river basin [11]. Then came the reports from 2023 and 2024. Health agencies in Brazil, Peru, Bolivia, Colombia, and Cuba started reporting thousands of laboratory-tested cases [7, 8]. What surprised epidemiologists was that cases were showing up in places where the virus had not been common before, including eastern Brazilian states like Bahia and Rio de Janeiro, as well as across the island of Cuba [8]. At the same time, doctors in Brazil reported two fatal cases in young women in Bahia along with cases where pregnant women with OROV fever suffered miscarriages or gave birth to infants with microcephaly [10, 17]. Travelers flying home from Cuba and South America to Europe and the United States also arrived at clinics with the fever [9]. In epidemiology, expanding PCR testing naturally uncovers cases that used to go missed, so we are not claiming a global pandemic—only noting why the WHO and PAHO asked hospitals to pay closer attention [7, 8].

1.3 Genetic Mixing and the Concept of Reassortment

One theoretical explanation discussed in recent genetics papers involves how segmented viruses behave. Because OROV keeps its RNA in three separate pieces (L, M, and S), two slightly different strains might occasionally infect the exact same cell inside a midge or animal [4]. When new virus particles are put together inside that cell, the segments can get mixed and matched—a process virologists call genetic reassortment. Sequencing teams in Brazil suggested that many 2023–2024 cases involved a reassortant strain (often labeled BR-2015-2024) that combined an M segment from one older Amazon strain with L and S segments from another [10]. In theory, this kind of genetic mixing might help a virus grow faster in lab dishes or adapt to new areas, though how much it changes human illness remains an open research question.

2. Conceptual Scope and Academic Disclaimer (No Claims)

2.1 Why a Pharmacy Student Is Reviewing This Topic

As a final-year Bachelor of Pharmacy (B. Pharm) student at Jagadambha Institute of Pharmacy And Research, my training focuses on how medicines work, how drugs are formulated, what side effects they cause, and how pharmacists help patients safely in everyday clinics. When you read about an emerging viral fever that has no specific cure, you start thinking about it from two angles. First, what happens in a local pharmacy when someone walks in with a high fever and body pain? Second, if medicinal chemists wanted to design a drug against this virus in the future, which viral enzymes would they try to block on paper?

In our B. Pharm syllabus in Maharashtra, we study subjects like Pharmacology, Medicinal Chemistry, Pharmaceutics, and Pharmacognosy. Sometimes those subjects can feel disconnected when we just memorize chemical rings for exams. Looking at an actual neglected virus like OROV helps us see how all those subjects fit together on paper: how a virus protein folds, why a prodrug needs cell enzymes to work, why certain painkillers affect blood platelets, and why keeping an mRNA vaccine cold in a hot rural clinic is so tough.

In this review, I wanted to bring together what published papers say about Oropouche virus and write it down in plain, understandable language for fellow pharmacy students. We look at the basic shape of the virus, how tiny biting midges carry it, how the illness feels to a patient, why common painkillers like ibuprofen can be risky when dengue is around, and what kinds of experimental molecules or vaccine ideas have been talked about in scientific journals.

2.2 Explicit Non-Clinical and Theoretical Disclaimer

To avoid any misunderstanding, I want to state as clearly as possible that this entire review is purely conceptual and educational, and makes zero claims of clinical efficacy, diagnostic accuracy, or medical treatment success. Right now, no regulatory body—whether the US FDA, the European Medicines Agency (EMA), the WHO, or India's CDSCO—has approved any antiviral drug or vaccine for Oropouche virus [7, 9]. Whenever we mention drugs like ribavirin, favipiravir, sofosbuvir, or brequinar in later chapters, we are only discussing them as theoretical examples from cell-culture papers or computer modeling ideas [13, 14]. We are not claiming that any of these medicines cure Oropouche fever or should be given to patients.

Similarly, every clinical feature, outbreak figure, and laboratory testing method summarized in this paper comes from published epidemiology reports and public health advisories rather than original clinical work by the authors. Patients with high fever, severe headache, bleeding signs, or fever during pregnancy must always seek evaluation from a qualified physician.

2.3 How This Conceptual Review Is Organized

To keep the reading logical for pharmacy students, the following sections move step by step from basic virology (virus structure and three RNA segments) to insect transmission cycles, cellular pathogenesis, clinical symptoms, pregnancy reports, differential diagnosis against dengue and chikungunya, and laboratory diagnostics. The final chapters explore theoretical drug targets, repurposed molecules studied in lab dishes, antibody and vaccine design concepts, midge vector control, and the practical everyday role of community pharmacists.

3. Virus Structure, Rna Segments, and Proteins (Theoretical Model)

3.1 Virion Shape and Negative-Sense RNA Segments

Based on electron microscope studies, the Oropouche virus particle (virion) is round and measures roughly 80 to 120 nm across [15]. Its outer surface is a fatty lipid membrane stolen from the host cell's Golgi apparatus, studded with 5 to 10 nm protein spikes made of Gn and Gc glycoproteins [15, 16]. Because it wears a host lipid envelope, simple soap, alcohol hand rubs, or drying in sunlight easily break the particle apart on surfaces—which is why OROV needs a biting insect rather than surface contact to spread. Inside sit three coiled negative-sense single-stranded RNA segments—Large (L), Medium (M), and Small (S)—whose matched 5' and 3' ends form a panhandle landing pad for viral copying [15].

3.2 Roles of the L, M, and S Segments

The L segment (~6,850 bases) codes for the 259 kDa L protein, which acts as the viral RNA-dependent RNA polymerase (RdRp) with a right-hand catalytic palm holding two magnesium ions [15]. Its N-terminal endonuclease pocket cuts 5' methylated caps off host mRNAs ('cap-snatching') so host ribosomes can read viral mRNA [15]. The M segment (~4,360 bases) produces a precursor snipped into Gn (~32 kDa, cell attachment), NSm (~12 kDa, Golgi assembly), and Gc (~110 kDa, a class II fusion protein that unfolds at acidic endosomal pH < 6.0) [16]. The S segment (~960 bases) uses overlapping frames to encode the nucleocapsid N protein (~25 kDa, shields viral RNA) and non-structural NSs (~10.5 kDa), which enters the nucleus and degrades host RNA Polymerase II (Rpb1) to silence early interferon warnings [5].




Fig. 1: Conceptual diagram of the Oropouche virus particle and its three negative-sense RNA segments (L, M, and S), showing the polymerase, surface spikes (Gn/Gc), and nucleocapsid coat.

Table 1: Basic Summary of Oropouche Virus RNA Segments and Proteins (Conceptual Overview).

RNA Segment	Approx. Size	Proteins Made	Weight	Conceptual Role Discussed in Literature
Large (L)	~6,850 bases	L Protein (Viral RdRp)	~259 kDa	Copies viral RNA and snatches 5' caps from host mRNA so viral proteins can be made.
Medium (M)	~4,360 bases	Gn, Gc Spikes & NSm	~32, 110, 12 kDa	Gn attaches to host cells; Gc fuses with acidic endosome wall; NSm aids Golgi assembly.

Small (S)	~960 bases	N Protein & NSs	~25, 10.5 kDa	N wraps viral RNA safely; NSs breaks down host RNA Pol II to slow interferon response.

4. How the Virus Spreads: Biting Midges and Forest Cycles

4.1 Culicoides paraensis Biting Midges and Where They Breed

Unlike dengue, which relies on mosquitoes, Oropouche fever in towns is mainly passed from person to person by tiny biting midges called Culicoides paraensis ('maruim' or 'no-see-ums') [6]. Measuring only 1.0 to 1.5 mm long, these quiet midges fly straight through standard mosquito bed nets (1.2–1.5 mm mesh) and bite most heavily around sunrise and sunset [6]. Crucially, midge larvae do not grow in clean water buckets; instead, females lay eggs in damp, rotting plant waste such as discarded cacao pod shells, chopped banana trunks, wet leaf litter, and compost piles near homes [6, 11]. Clearing standing water alone does not stop midge breeding.

4.2 Wild Forest (Sylvatic) vs. Town (Urban) Cycles

In the rainforest canopy, OROV circulates quietly between wild hosts—three-toed sloths (Bradypus tridactylus), monkeys (howler, capuchin, marmoset), rodents, and forest birds—carried by forest mosquitoes like Coquillettidia venezuelensis and Aedes serratus [1, 2]. Town outbreaks start when someone enters cleared forest edges, gets bitten, and returns home with high blood virus levels (Days 1–5 of fever). Local C. paraensis midges pick up the virus and spread it between neighbors, while deforestation and warm El Niño rains expand midge habitats [2, 11].




Fig. 2: Conceptual illustration of the wild forest cycle (involving sloths, monkeys, and forest mosquitoes) and the town cycle driven by Culicoides paraensis biting midges.

Table 2: Comparison of Main and Secondary Insects Linked to Oropouche Virus in Literature.

Insect Name	Group	Biting Window	Larval Habitat	Conceptual Role in Spread
Culicoides paraensis	Biting midge	Sunrise, sunset & humid afternoons	Damp rotting cacao shells, banana stalks & compost	Main town vector spreading OROV between people.
Culex quinquefasciatus	House mosquito	Nighttime indoors	Dirty standing water & clogged drains	Possible secondary urban carrier; less efficient than midges.
Coquillettidia venezuelensis	Forest mosquito	Daytime & evening in woods	Swamps & marshes with floating plants	Forest cycle vector; first insect isolated in 1955.
Aedes serratus	Forest mosquito	Daytime under dense canopy	Rain puddles & wet forest leaf litter	Thought to circulate OROV among sloths and monkeys.

5. How The Virus Enters Cells and Causes Illness (Theoretical Model)

5.1 Skin Entry, Endocytosis, and Acid-Triggered Fusion

When an infected female C. paraensis midge nicks skin capillaries, her saliva keeps tiny vessels open, slows local platelet clotting, and delivers virus particles right next to skin dendritic cells and tissue macrophages [15]. The viral Gn spike is thought to bind sugar-protein chains (like heparan sulfate) on

host cell membranes, triggering clathrin-mediated endocytosis into an internal vesicle (endosome) [16]. As host proton pumps push hydrogen ions inside and lower endosomal pH below 6.0, the Gc glycoprotein unfolds and pokes its hydrophobic fusion loop into the vesicle wall, merging the membranes so the three viral RNA loops slip into the cytoplasm [16].

5.2 Viral Copying in the Cytoplasm and Golgi Assembly

Inside the cytoplasm, the packed viral L polymerase snatches 5' caps from host mRNAs to transcribe viral mRNAs for host ribosomes [15]. Once enough nucleocapsid (N) protein accumulates, the L protein switches to full-length positive-sense cRNA and brand-new negative-sense vRNA copies [15]. Meanwhile, Gn and Gc spikes fold in the endoplasmic reticulum and travel to the Golgi apparatus. Rather than budding off the outer cell surface, new virus particles bud directly into internal Golgi sacs and ride out inside secretory bubbles, staying partly shielded until release.

5.3 Silencing Interferon (NSs), Cytokines, and Brain Entry Theories

Normally, cell sensors like RIG-I trigger Type-I interferons to warn nearby tissues. However, the viral NSs protein enters the nucleus and causes degradation of host RNA Polymerase II (Rpb1), silencing early interferon transcription [5]. Surrounding immune cells still detect damage and release cytokines (TNF-alpha, IL-6, IL-1beta), which stimulate hypothalamic PGE2 prostaglandins to raise body temperature and cause chills and body aches [12]. In rodent studies, high blood viral levels and cytokine-loosened blood-brain junctions—or upward travel along olfactory nerves—have been proposed as theoretical routes to the central nervous system [12].




Fig. 3: Conceptual diagram of how Oropouche virus is thought to enter a host cell, copy its RNA, block host RNA Polymerase II via NSs, and where theoretical drug ideas might act.

6. Symptoms and Clinical Picture Reported In Literature

6.1 Sudden Fever, Eye Pain, and Stomach Upset

After a quiet incubation period of roughly 3 to 8 days following a midge bite, illness starts abruptly with high fever (39°C–40°C), chills, severe headache, and deep aching pain behind the eyes (retro-orbital pain) paired with bright-light sensitivity (photophobia) [2, 9]. Patients also report strong back and leg muscle aches, joint pain, nausea, vomiting, and occasional diarrhea, making oral fluids and ORS essential. Simple non-drug comfort steps like resting in a quiet, shaded room with a cool damp forehead cloth are commonly used alongside hydration. Around days 3 to 5, roughly one in four patients develops a flat, non-itchy reddish rash on the chest or arms that fades on its own [11].

6.2 The Two-Wave (Bimodal) Relapse Pattern

A hallmark feature of Oropouche fever is its bimodal relapse: the first fever clears after 3 to 5 days, making patients feel recovered, but in roughly 40% to 60% of cases, fever, eye pain, and fatigue return 2 to 10 days later for a few more days [2, 11]. From a pharmacy perspective, patients often mistake this relapse for a new bacterial infection like typhoid and request antibiotics such as azithromycin, amoxicillin, or ciprofloxacin—which act only on bacteria and do nothing against RNA viruses.

6.3 Brain Lining Irritation and 2024 Severe Reports

While ordinary headaches come from fever cytokines, roughly 1% to 4% of clinic cases develop true aseptic meningitis or meningoencephalitis with stiff neck, dizziness, or confusion,

where spinal fluid shows lymphocytes and viral RNA or IgM [12]. Mild bleeding signs (nosebleeds, gum bleeding, petechiae) with lower platelets can also occur. In 2024, Bahia, Brazil reported two rare fatal cases in young women with severe bleeding and organ failure, underscoring that any tropical fever with warning signs requires immediate hospital evaluation [10, 17].




Fig. 4: Conceptual timeline of Oropouche fever showing the initial fever wave, the common relapse wave a week later, viral RNA levels in blood, and IgM/IgG antibody rise.

7. Pregnancy Concerns and Mother-To-Child Transmission Reports

7.1 Why 2024 Changed How Researchers View Pregnancy Risk

For many decades, nobody knew for sure whether Oropouche virus could harm an unborn baby during pregnancy. Veterinarians had long observed that related Simbu-group viruses—such as Akabane virus and Schmallenberg virus—cause birth defects and stillbirths in pregnant cattle and sheep [17]. Then, during the 2024 outbreak in Brazil, doctors reported several cases where pregnant women with lab-confirmed Oropouche fever suffered miscarriages, stillbirths, or delivered infants with congenital brain abnormalities including microcephaly [7, 17]. Epidemiological studies are still working out how frequently this occurs, so we do not claim exact risk percentages, but these observations prompted urgent public health advisories from WHO, PAHO, and the CDC [7–9].

7.2 Conceptual Idea of How the Virus Might Cross the Placenta

In the cases investigated by Brazilian health authorities, laboratory testing detected OROV RNA and specific antibodies inside placental tissue, umbilical cord blood, and fetal organ samples [17]. Conceptually, researchers suggest that when a pregnant woman has high virus levels circulating in her blood during the first few days of fever, the virus may infect outer placental cell layers (trophoblast cells). If placental inflammation reduces oxygen delivery or weakens the barrier, virus particles might enter fetal circulation. In human physiology, the placenta normally acts as a remarkably strong filter keeping most microbes away from the fetus, leaving only a small group (classic TORCH pathogens plus Zika) capable of crossing; how readily OROV crosses remains under active investigation.

7.3 Possible Effects on the Developing Fetal Brain

Once inside fetal circulation, orthobunyaviruses appear to show a strong attraction (tropism) for immature, dividing nerve cells in the developing brain [12, 17]. Because a fetus does not yet possess a mature interferon defense system, viral replication could damage neural progenitor cells, potentially leading to cell death, fluid buildup (hydrocephalus), or reduced head size (microcephaly)—resembling patterns seen earlier during the Zika epidemic. Scientists are still investigating whether specific reassortant strains carry greater risk or whether earlier cases simply went undetected.

7.4 Practical Precautions Discussed by Health Agencies

Because no licensed vaccine or antiviral tablet exists to protect an unborn baby from OROV, public health guidance focuses completely on preventing midge bites during pregnancy [8, 9]. Agencies advise pregnant women in outbreak areas to stay indoors during early morning and late afternoon biting peaks, install ultra-fine mesh (<0.6 mm) on windows and beds, wear long sleeves, and apply approved skin repellents (such as DEET or Picaridin) per label directions. When a pregnant woman in an endemic area develops fever, clinicians test for OROV alongside dengue and Zika and monitor fetal growth closely by ultrasound [9].

8. Telling Oropouche Apart From Other Tropical Fevers

8.1 Dengue Overlap and the Practical NSAID Warning

In South America and the Caribbean, Oropouche fever overlaps directly with dengue, and doctors cannot tell them apart by symptoms alone [8, 11]. While OROV often shows a two-wave relapse, dengue carries a dangerous critical phase around days 5 to 7 with vascular fluid leak and steep platelet drops. This

brings up a vital B. Pharm pharmacology rule: aspirin and NSAIDs (ibuprofen, diclofenac, naproxen) must be avoided in suspected arboviral fevers. Aspirin irreversibly blocks platelet COX-1 for 7–10 days, and other NSAIDs impair clotting and irritate the stomach—risking serious hemorrhage if the patient has dengue or low platelets. Standard guidelines therefore favor paracetamol (within safe adult limits below 4 g/day) for fever and pain [9].

8.2 Chikungunya, Zika, Mayaro, Yellow Fever, and Non-Viral Fevers

Chikungunya and Mayaro are best known for causing intense, swollen small-joint pain (wrists, ankles, fingers) that can linger for months, whereas OROV aches usually clear after the fever ends [11]. Zika typically produces a milder fever with an itchy rash and non-purulent red eyes, though both Zika and OROV raise pregnancy concerns. Yellow fever causes severe jaundice and liver/kidney injury. Non-viral mimics like malaria (checked via rapid strip or blood smear) and leptospirosis (treated with prescribed antibiotics) must also be ruled out using multiplex laboratory panels [18].

Table 3: General Comparison of Oropouche Fever with Other Tropical Fevers (Educational Summary).

Feature	Oropouche Fever	Dengue Fever	Chikungunya	Zika Virus
Fever Pattern	Sudden high fever; often relapses 2–10 days later.	High fever 5–7 days; fluid leak risk as fever drops.	Sudden fever 3–5 days; usually single wave.	Mild fever or sometimes no fever at all.
Headache & Eyes	Strong pain behind eyes & light sensitivity.	Heavy headache & retro-orbital pain.	Moderate headache; eye pain less common.	Mild headache; red eyes without pus.
Muscles & Joints	Body & joint aches that clear after recovery.	Severe muscle/bone aches ('break-bone').	Very painful swollen joints lasting months.	Mild muscle/joint pain clearing quickly.
Skin Rash	Flat red rash in ~25%; rarely itchy.	Red rash often appearing as fever drops.	Rash in ~50% of cases.	Itchy red rash across face & body.
Bleeding Risk	Occasional nose/gum bleeds or petechiae.	Major platelet drop, bleeding & shock risk.	Rare and usually mild.	Very rare.
Nervous System	Occasional meningitis-like irritation (1–4%).	Rare; mostly tied to shock/liver injury.	Occasional nerve weakness.	Linked to Guillain-Barré & microcephaly.

9. Laboratory Testing Methods Described In Literature

9.1 Sample Collection, Cold Chain, and RT-qPCR (Days 1–5)

Laboratory testing for OROV depends strictly on how many days the patient has been sick [18]. During Days 1 to 5, when viral RNA circulates actively in the blood, reverse transcription quantitative PCR (RT-qPCR) on chilled serum or plasma (kept at 2°C–8°C or -80°C) is the primary diagnostic method [18]. Labs target conserved regions of the Small (S) or Large (L) segment so reassorted M segments do not cause false negatives; urine, saliva, or spinal fluid (CSF, in meningitis cases) have also been tested [12, 18]. Once blood viral levels fall after day 5, RT-qPCR may turn negative even in true infections.

9.2 Antibody Tests (ELISA), PRNT Cross-Reaction, and Biosafety

From day 5 onward, IgM antibody-capture ELISA (MAC-ELISA) detects early antibodies, while paired IgG ELISA samples taken two weeks apart look for rising titers [18]. Because related Simbu-group viruses (like Iquitos or Caraparu) can cross-react on standard ELISA plates, reference labs use a Plaque Reduction Neutralization Test (PRNT) on cultured Vero cells—checking whether patient serum prevents live virus from creating clear cell-death plaques [4, 18]. Routine RNA extraction and ELISA run under Biosafety Level 2 (BSL-2), whereas growing live OROV for PRNT requires Biosafety Level 3 (BSL-3) containment [18]. Because rural clinics lack PCR machines, rapid finger-prick antigen/IgM strips remain an important conceptual research need.

Table 4: Summary of Laboratory Testing Methods Discussed in Literature.

Test Type	Target Detected	Sample & Biosafety	Best Timing	Conceptual Notes & Limitations
RT-qPCR	Viral S or L segment RNA	Serum, plasma, CSF, or urine (BSL-2)	Days 1 to 5 of fever	Highly sensitive early on; turns negative once virus clears from blood.
IgM ELISA (MAC-ELISA)	Early anti-OROV IgM antibodies	Blood serum or CSF (BSL-2)	Day 5 up to ~1 month	Useful after viremia ends; related Simbu viruses may cross-react.
IgG ELISA	Long-term IgG	Paired serum 2 weeks	After day 10 of	Demonstrates rising antibody

	antibodies	apart (BSL-2)	illness	levels between acute and recovery phases.
Neutralization (PRNT)	Antibodies blocking live virus	Paired blood serum (BSL-3 live virus)	After 2 weeks of illness	High specificity, but takes several days and needs specialized labs.
Rapid Strip Concept	Viral N protein or IgM	Finger-prick blood (Clinic / BSL-2)	Days 1–7 (Ag); Day 5+ (IgM)	Point-of-care concept for rural clinics without PCR equipment.

10. Outbreak History and Environmental Factors (Literature Summary)

10.1 Seventy Years of Outbreaks (1955–2026)

Following the 1955 forest worker case in Trinidad [1], the first major urban epidemic struck Belém, Brazil in 1961 (~11,000 cases) [2]. Over the 1970s–1990s, repeated waves hit Pará, Maranhão, Amazonas (over 100,000 cases in Manaus in 1980–1981), and Iquitos, Peru, totaling over half a million estimated infections—though mild home cases mostly went uncounted [2, 3, 11]. In 2023–2024, over 10,000 lab-confirmed cases expanded beyond the Amazon into eastern Brazil, Bolivia, Peru, Colombia, and Cuba alongside over 100 travel-associated cases in the US and Europe [7, 8, 10].

10.2 Deforestation, Farm Waste, and Climate Patterns

Ecological reports link outbreaks directly to road building, forest clearing, and farming near jungle edges [3, 11]. Planting cocoa and bananas creates damp heaps of rotting husks and stalks right next to homes, fueling C. paraensis surges. Warm, humid rainy seasons and El Niño weather shifts accelerate larval maturation, while ecological niche maps suggest warmer winters could gradually expand suitable midge zones across Central America and the Caribbean—purely conceptual models rather than guaranteed predictions.

Table 5: Timeline of Notable Oropouche Virus Outbreaks Reported in Scientific Literature (1955–2026).

Year(s)	Places Reported	Approx. Scale	Main Insect Noted	Why It Matters in Literature
1955	Vega de Oropouche, Trinidad	1 human case	Forest mosquitoes	First isolation of OROV from a patient and forest mosquitoes.
1961	Belém, Pará, Brazil	~11,000 cases	Culicoides paraensis	First large town epidemic; linked urban spread to biting midges.
1975	Maranhão & Pará, Brazil	>30,000 cases	Culicoides paraensis	Outbreaks followed highway construction and forest clearing.
1980–81	Manaus, Amazonas, Brazil	>100,000 cases	Midges & Culex	Demonstrated wide transmission inside a major Amazon city.
1992–94	Iquitos, Loreto, Peru	>15,000 cases	Culicoides paraensis	Confirmed large endemic outbreaks in the Peruvian Amazon.
2016	Cusco & Madre de Dios, Peru	Several thousand	Culicoides paraensis	Cases appeared in higher-altitude foothill towns.
2023–24	Brazil, Bolivia, Peru, Cuba	>10,000 confirmed	Midges & Culex	Spread to new states & Cuba; reassortant strain & pregnancy alerts.
2024–26	Travelers to US & Europe	>100 travel cases	No local spread	Imported cases in returning travelers triggered global advisories.

11. Theoretical Drug Targets in the Virus Life Cycle (Conceptual Only)

11.1 Viral RNA Polymerase (RdRp) and Cap-Snatching Endonuclease

Switching to a B. Pharm medicinal chemistry lens—while repeating that no approved antiviral exists for OROV—we can ask which viral pockets make logical targets on paper. First is the RNA-dependent RNA polymerase (RdRp) inside the L protein [15]. In medicinal chemistry, this follows Paul Ehrlich's principle of selective toxicity: because human cells do not copy RNA from RNA, selective nucleoside analogues could theoretically jam the magnesium-binding palm pocket, though human mitochondrial RNA polymerase cross-toxicity always requires careful safety testing.

Second is the L protein's N-terminal cap-snatching endonuclease pocket [15]. Much like the approved influenza drug baloxavir marboxil uses a metal-chelating group to grip two metal ions inside the flu cap-snatching enzyme, diketo acids or metal-chelating rings have been discussed conceptually for bunyavirus endonucleases.

11.2 Blocking Gc Fusion and Host Nucleotide Enzymes (DHODH)

A third **theoretical** target is the Gc surface spike: small molecules or peptides locking its hinge region could prevent acid-triggered fusion inside endosomes, conceptually similar to the HIV fusion peptide enfuvirtide [16]. A fourth, host-directed concept involves slowing human dihydroorotate dehydrogenase

(DHODH) to reduce cellular UTP and CTP pools needed for rapid viral RNA synthesis—though blocking host enzymes carries inherent risks for rapidly dividing human tissues.




Fig. 5: Conceptual grouping of theoretical antiviral ideas discussed in academic literature (polymerase/endonuclease blockers, host enzyme blockers, and antibody concepts). No clinical claims are made.

12. Conceptual Ideas on Repurposing Existing Drugs (No Clinical Claims)

12.1 In Vitro Repurposing vs. Real-World Clinical Reality

Because developing a new antiviral takes 10–15 years, academic labs often screen existing medicines against bunyaviruses in plastic cell-culture dishes. Crucially, dish activity (in vitro) never proves a drug works in patients. Ribavirin slowed OROV in Vero cells via host IMPDH inhibition and viral mutagenesis [13], but its charged triphosphate gets trapped inside red blood cells (which lack phosphatases to remove it), causing hemolytic anemia, and it is strictly contraindicated in pregnancy (FDA Category X). Favipiravir (T-705), an influenza prodrug converted to favipiravir-RTP, stalls bunyavirus polymerases in lab models but requires large doses and carries embryo safety warnings [14]. Sofosbuvir, a hepatitis C ProTide uridine prodrug whose phosphoramidate mask helps it cross cell membranes, reduced OROV replication at high micromolar concentrations in cultured cells, yet lacks clinical evidence for OROV [14].

12.2 Host Blockers, Endosome pH Drugs, and Computer Docking

Host DHODH blockers (brequinar, teriflunomide) and mycophenolic acid lowered viral yields in lab flasks but risk immune suppression and bone marrow toxicity. Weak bases like chloroquine raise endosomal pH in dishes yet repeatedly failed human arbovirus trials and carry QT-prolongation risks. Likewise, computer docking of plant flavonoids (quercetin, curcumin) is useful for student SAR training, not proof of clinical efficacy.

Table 6: Summary of Repurposed Drugs Discussed as Theoretical Lab Concepts (None Approved for OROV).

Drug Name	Chemical Group	Theoretical Target	Proposed Lab Mechanism	Key Limitations (Not Approved)
Ribavirin	Guanosine analogue	Host IMPDH & RdRp	Lowers GTP pools; induces viral RNA copying errors in dishes.	Hemolytic anemia (RBC trap) & strict pregnancy contraindication.
Favipiravir (T-705)	Pyrazine-carboxamide	Viral RdRp pocket	Converted to active RTP mimicking purine bases in lab models.	High pill burden, no OROV trials, & teratogenic warnings.
Sofosbuvir	Uridine ProTide prodrug	Viral RdRp active site	Masks phosphate charge to enter cells; studied in neural dishes.	Purely exploratory; unclear if human doses reach active tissue levels.
Brequinar	Quinoline carboxylic acid	Host DHODH enzyme	Depletes cellular pyrimidine (UTP/CTP) supply in flasks.	Lab concept only; risks toxicity in rapidly dividing human cells.
Leflunomide	Isoxazole derivative	Host DHODH enzyme	Active form (teriflunomide) slows	Arthritis drug; very long half-life & strict pregnancy

			pyrimidine synthesis in vitro.	warnings.

13. Theoretical Antibody and Immune Concepts (No Clinical Claims)

13.1 The Idea of Passive Antibody Transfer

In immunology and biopharmaceutics, when no small-molecule oral pill exists for a viral fever, researchers often examine antibody-based concepts. Again, everything in this section is purely academic—no antibody treatment exists for Oropouche fever today. Early laboratory studies checked whether serum taken from animals or humans who recovered from OROV could neutralize the virus in cell dishes or protect rodents [15]. While convalescent serum antibodies can bind viral particles in test tubes, whole plasma is impractical for routine clinics because antibody levels vary widely across donors, supplies are scarce, and blood products demand rigorous pathogen screening.

13.2 Monoclonal Antibody Concepts Aimed at Gn and Gc Spikes

Instead of whole plasma, pharmaceutical biotechnology focuses conceptually on lab-engineered monoclonal antibodies (mAbs) directed at the outer Gn and Gc surface spikes [16]. On paper, an antibody binding tightly to Gn could block initial host-cell attachment, while an antibody locking onto domain II of Gc near its hydrophobic fusion loop could prevent acid-triggered membrane fusion inside endosomes. From a pharmaceutics standpoint, however, mAbs are large (~150 kDa) proteins destroyed by stomach acid and pepsin if swallowed, meaning they require sterile injection, expensive bioreactor production, and cold-chain refrigerators—major barriers for rural tropical clinics.

13.3 Single-Domain Nanobodies: A Theoretical Brain-Delivery Idea

A common pharmacology question is how a large 150 kDa IgG antibody could help if a virus crosses into the brain, since intact IgG barely crosses the blood-brain barrier. Biotechnology literature discusses camelid single-domain antibody fragments—called VHH nanobodies (~15 kDa, one-tenth the size of regular antibodies). Because nanobodies are tiny and heat-stable, researchers have explored whether future engineered nanobodies could reach recessed viral pockets or cross vascular barriers more readily. For OROV, this remains purely a conceptual idea.

13.4 Lab Studies on Interferon Timing

Because the viral NSs protein shuts down host Type-I interferon production [5], laboratory experiments tested adding recombinant interferon-alpha or interferon-beta to cells or mice very early after viral exposure. Early treatment activated antiviral genes before the virus could establish itself, whereas late dosing after high fever is already underway generally shows poor benefit and causes flu-like side effects of its own.

14. Conceptual Vaccine Design Ideas for Future Study

14.1 Inactivated, Weakened Live (Delta-NSs), and Viral Vector Ideas

No licensed human vaccine exists for Oropouche virus today [7, 9], yet reviewing standard biotechnology platforms helps students understand vaccine design on paper. A traditional inactivated (killed) whole-virus vaccine treated with formalin or beta-propiolactone—similar to inactivated polio (IPV) or rabies vaccines—cannot replicate, making it theoretically safer for vulnerable groups like pregnant women, though it typically needs booster doses. A weakened live-attenuated concept deletes the NSs gene (OROV-Delta-NSs) so the virus cannot block host interferon [5]; while strong in theory, live bunyaviruses raise concerns about genetic reassortment with wild strains and pregnancy safety. Viral vector concepts place OROV Gn/Gc genes inside harmless carriers like rVSV or adenovirus to display spikes safely.

14.2 mRNA-LNP, Virus-Like Particles (VLPs), and Lab Animal Models

Synthetic mRNA encoding Gn and Gc packaged inside four-component lipid nanoparticles (ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid to protect mRNA from RNases and aid endosomal escape) could theoretically be updated rapidly if new reassortants appear, though ultra-cold storage is tough in hot Amazon villages. Empty virus-like particles (VLPs) assemble Gn, Gc, and N proteins without any viral RNA. Early preclinical testing relies on IFNAR-/- mice or Golden Syrian hamsters, which are only initial steps far removed from human proof.

Table 7: Conceptual Comparison of Vaccine Platforms Discussed for Future Research (None Licensed).

Vaccine Idea	Viral Component	Theoretical Immune Goal	Conceptual Pros & Cons	Current Stage
Inactivated Virus	Chemically killed whole virus	Induce antibodies against surface Gn/Gc spikes.	Cannot replicate (safer in theory), but needs booster shots.	Early lab concept only.
Weakened Live (Delta-NSs)	Virus lacking NSs gene	Trigger both antibodies & T-cells after one dose.	Strong response in theory; reassortment & pregnancy safety risks.	Cells & mouse models only.
Viral Vector (rVSV / Adeno)	Harmless carrier + Gn/Gc genes	Host cells express viral spikes safely.	Established platform; prior immunity to carrier may	Experimental research stage.

			reduce effect.	
mRNA-LNP	Synthetic Gn/Gc mRNA in lipids	Temporary spike expression in muscle cells.	Fast to update on paper; cold-chain storage challenge in rural areas.	Conceptual design only.
Virus-Like Particles (VLPs)	Empty Gn/Gc/N protein shells	Display native surface shape with zero RNA.	Non-infectious & safe in theory; complex manufacturing.	Early academic exploration.

15. Practical Ideas for Controlling Midges and Preventing Bites

15.1 Environmental Cleanup vs. Chemical Sprays

Without approved antivirals or vaccines, preventing midge bites is the main public health defense [8, 9]. Because C. paraensis larvae thrive in damp decaying plant matter rather than open water buckets, spreading out rotting cacao husks and banana stalks to dry in the sun or composting them far from sleeping quarters cuts down midge nurseries at low cost and without insecticide resistance [6]. Outdoor pyrethroid fogging knocks down flying adults only briefly because midges shelter under foliage and new adults emerge from damp compost; indoor wall spraying and larvicides face rain and thick compost penetration hurdles, while natural agents (Bti bacteria, Beauveria fungi) degrade quickly in tropical sunlight.

15.2 Personal Protection and Entomological Trapping

Standard mosquito nets (1.2–1.5 mm holes) let 1 mm midges pass right through [6]. Effective physical barriers require ultra-fine micro-mesh (<0.6 mm holes) or permethrin-treated netting, paired with long sleeves and approved skin repellents (DEET 20%–30%, Picaridin, or oil of lemon eucalyptus) during sunrise and sunset biting peaks [9]. Field teams also run CO2-baited UV light traps and test pooled midges by RT-qPCR to spot local outbreaks early.

Table 8: Practical Vector Control and Bite Prevention Ideas Discussed in Literature.

Control Area	Practical Measure	Target Stage	How It Helps in Theory	Everyday Challenges
Plant Waste Cleanup	Drying or composting cacao shells & banana stems.	Eggs, larvae & pupae	Removes damp organic nurseries where females lay eggs.	Requires steady community effort during harvest seasons.
Wall Spray & Fogging	Indoor wall spraying or outdoor pyrethroid fog.	Adult flying/resting midges	Kills adult insects contacting treated surfaces.	Outdoor fog fades fast in rain; midges hide under leaves.
Soil Larvicides	Insect growth regulators on wet compost heaps.	Larvae in organic soil	Prevents larvae from maturing into biting adults.	Sprays struggle to penetrate deep inside thick husk piles.
Biological Helpers	Bti bacteria or Beauveria fungi in breeding spots.	Larvae or adult midges	Gentler on environment than heavy chemical sprays.	Tropical sunlight and rain rapidly weaken biological agents.
Personal Protection	Ultra-fine mesh (<0.6 mm) & DEET/Picaridin.	Biting female midges	Physically blocks tiny midges and repels skin bites.	Fine mesh reduces airflow in heat; repellents need re-applying.

16. Community Health, Pharmacy Awareness, and One Health Concepts

16.1 The 'One Health' Connection

Oropouche virus illustrates the 'One Health' principle—that human health, wildlife ecology, and the environment are tightly linked [11]. Much like Kyasanur Forest Disease ('monkey fever') in India's Western Ghats, where ticks carry a forest virus from monkeys to villagers entering the woods, OROV circulates quietly in forest sloths and monkeys until deforestation and farm waste bring people and biting insects together. Sharing lab protocols and travel alerts across borders through PAHO and WHO networks helps hospitals recognize imported fevers quickly [7, 8].

16.2 How Community Pharmacists Can Guide Patients Safely

Without claiming to diagnose or cure viral fevers, community pharmacists play a very practical role during tropical fever seasons: (1) Referring red-flag patients immediately to a hospital if they show bleeding gums, severe abdominal pain, persistent vomiting, stiff neck, confusion, or fever during pregnancy; (2) Explaining why paracetamol (within safe daily limits) is preferred and why aspirin/NSAIDs (ibuprofen, diclofenac, naproxen) must be avoided until dengue or platelet drops are ruled out; (3) Promoting oral hydration with clean water and ORS; (4) Advising kindly against unnecessary antibiotics during the natural second-wave fever relapse; and (5) Sharing practical midge bite prevention tips such as ultra-fine mesh (<0.6 mm) and DEET or Picaridin skin repellents [9].




Fig. 6: Conceptual One Health diagram showing how wildlife monitoring, midge control, community pharmacy education, and lab testing connect together.

17. Summary of this Conceptual Student Review

17.1 Bringing Together the Main Points

Working through the scientific literature on Oropouche virus shows how a once-overlooked forest virus can grow into a significant public health topic across the Americas [7, 11]. In this conceptual review, we traced how OROV is assembled from three negative-sense RNA segments (L, M, and S), how its NSs protein silences host interferon warnings by degrading RNA Polymerase II, and how tiny 1-millimeter Culicoides paraensis midges breed in rotting cacao shells and banana stalks to drive town outbreaks [5, 6]. We also examined the abrupt fever, retro-orbital pain, the characteristic two-wave relapse in nearly half of cases, and the 2024 reports highlighting rare neurological irritation and pregnancy concerns [8, 12, 17].

17.2 Connecting Virology with Pharmacy Education

Putting this review together as a final-year B. Pharm student at Jagadambha Institute of Pharmacy And Research shows how classroom subjects—microbiology, pharmacology, medicinal chemistry, pharmaceutics, and community pharmacy—connect directly to real-world public health questions. At every step, we have kept this document strictly conceptual and educational, making zero claims of clinical efficacy for any experimental drug or vaccine candidate.

Table 9: Quick Academic Summary of Core Concepts for Pharmacy Students.

Domain	Core Concept Summarized in This Review
Virology	Enveloped three-segment negative-sense RNA Orthobunyavirus (L, M, S); reassortment possible.
Vector Ecology	Spread in towns mainly by tiny Culicoides paraensis midges breeding in rotting cacao/banana waste.
Clinical & Pharmacy Care	Sudden fever + ~40–60% relapse; supportive fluids & paracetamol only; avoid aspirin/NSAIDs & unnecessary antibiotics.
Diagnostics	RT-qPCR on Days 1–5 (blood viremia); IgM/IgG ELISA from Day 5+; PRNT for Simbu cross-reaction.
Exploratory Research	Theoretical targets (RdRp, endonuclease, Gc fusion, DHODH) & vaccine platforms remain conceptual; none approved.

18. Conclusion

To wrap up this conceptual review, Oropouche virus is a clear reminder that neglected tropical fevers deserve steady attention from pharmacy students, teachers, and healthcare workers. Even though the virus has been known since its first isolation in a forest worker in Trinidad in 1955 [1], its rapid expansion across South America and the Caribbean in 2023 and 2024 showed how quickly a quiet forest virus carried by tiny Culicoides paraensis midges can affect towns, farming communities, and international travelers [7, 8, 10].

Because there is still no approved antiviral tablet or licensed human vaccine for Oropouche fever anywhere in the world [9], everyday patient care rests entirely on simple, sensible supportive steps: keeping patients well hydrated with water and oral rehydration salts, using paracetamol safely within recommended daily limits for fever and body aches, staying strictly away from aspirin and NSAIDs like ibuprofen whenever dengue or bleeding risks cannot be ruled out, and explaining clearly why antibiotics do not help during the common second-wave fever relapse.

Equally important, practical community vector-control habits remain our strongest real-world defense against outbreaks. Because midge larvae grow in damp, rotting organic matter rather than clean standing water, drying or composting discarded cacao husks and banana stalks away from sleeping quarters cuts down breeding sites without chemical resistance [6]. Pairing environmental cleanup with ultra-fine window screens (<0.6 mm), protective clothing during sunrise and sunset biting hours, and approved skin repellents is especially critical for pregnant women living in or traveling to endemic regions [9, 17].

On the academic research side, studying the viral L RNA polymerase, the metal-binding cap-snatching endonuclease pocket, the acid-triggered Gc fusion spike, and theoretical vaccine platforms offers a rich foundation for classroom medicinal chemistry and pharmaceutical biotechnology learning [15, 16]. Keeping a humble, evidence-based mindset—where laboratory dish ideas and repurposed drug concepts (such as ribavirin, favipiravir, sofosbuvir, or DHODH blockers) are clearly separated from proven clinical cures—is one of the most important habits we can carry forward as future pharmacists.

References

1. Anderson CR, Spence L, Downs WG, Aitken TH. Oropouche virus: a new human disease agent from Trinidad, West Indies. Am J Trop Med Hyg. 1961; 10(4): 574-578. https://pubmed.ncbi.nlm.nih.gov/13683183/
2. Pinheiro FP, Travassos da Rosa AP, Travassos da Rosa JF, et al. Oropouche virus. I. A review of clinical, epidemiological, and ecological findings. Am J Trop Med Hyg. 1981; 30(1): 149-160. https://pubmed.ncbi.nlm.nih.gov/6782898/
3. Vasconcelos PF, Travassos da Rosa JF, Guerreiro SC, et al. First register of an epidemic caused by Oropouche virus in the states of Maranhão and Goiás, Brazil. Rev Inst Med Trop Sao Paulo. 1989; 31(4): 271-278. https://pubmed.ncbi.nlm.nih.gov/2516642/
4. Saeed MF, Li L, Wang H, Weaver SC, Barrett ADT. Phylogeny of the Simbu serogroup of the genus Bunyavirus. J Gen Virol. 2001; 82(9): 2173-2181. https://pubmed.ncbi.nlm.nih.gov/11514727/
5. Tilston-Lunel NL, Acrani GO, Randall RE, Elliott RM. Generation of recombinant Oropouche viruses lacking the nonstructural protein NSm or NSs. J Virol. 2015; 90(5): 2616-2627. https://pubmed.ncbi.nlm.nih.gov/26699638/
6. Mercer DR, Spinelli GR, Watts DM, Tesh RB. Biting rates and developmental substrates for biting midges (Diptera: Ceratopogonidae) in Iquitos, Peru. J Med Entomol. 2003; 40(6): 807-812. https://pubmed.ncbi.nlm.nih.gov/14765657/
7. World Health Organization (WHO). Oropouche virus disease - Region of the Americas. Disease Outbreak News. Geneva: WHO; 2024. https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON545
8. Pan American Health Organization (PAHO/WHO). Epidemiological Alert: Oropouche in the Region of the Americas. Washington, D.C.: PAHO/WHO; 2024. https://www.paho.org/en/documents/epidemiological-alert-oropouche-region-americas-1-august-2024
9. Centers for Disease Control and Prevention (CDC). Clinical Overview of Oropouche Virus Disease. Atlanta: CDC; 2024. https://www.cdc.gov/oropouche/hcp/clinical-overview/index.html
10. Naveca FG, Nascimento VAD, Souza VC, et al. Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region. Nat Med. 2024; 30(9): 2450-2458. https://pubmed.ncbi.nlm.nih.gov/39293488/
11. Romero-Alvarez D, Escobar LE. Oropouche fever, an emergent disease from the Americas. Microbes Infect. 2018; 20(3): 135-146. https://pubmed.ncbi.nlm.nih.gov/29247710/
12. Bastos MS, Figueiredo LT, Naveca FG, et al. Identification of Oropouche Orthobunyavirus in the cerebrospinal fluid of three patients in the Amazonas, Brazil. Am J Trop Med Hyg. 2012; 86(4): 732-735. https://pubmed.ncbi.nlm.nih.gov/22492162/
13. Livonesi MC, de Sousa RLM, Badra SJ, Figueiredo LTM. In vitro and in vivo studies of ribavirin action on Brazilian Orthobunyaviruses. Am J Trop Med Hyg. 2006; 75(5): 1011-1016. https://pubmed.ncbi.nlm.nih.gov/17124004/
14. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013; 100(2): 446-454. https://pubmed.ncbi.nlm.nih.gov/24084488/
15. Elliott RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014; 12(10): 673-685. https://pubmed.ncbi.nlm.nih.gov/25198140/
16. Hellert J, Aebischer A, Haouz A, et al. Structure, function, and evolution of the Orthobunyavirus membrane fusion glycoprotein. Cell. 2023; 186(6): 1221-1235. https://pubmed.ncbi.nlm.nih.gov/36827185/
17. Martins-Filho PR, Carvalho TA, dos Santos CA, et al. Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series. Lancet Infect Dis. 2025; 25(2): 155-165. https://pubmed.ncbi.nlm.nih.gov/39423837/
18. PAHO/WHO. Guidelines for the Detection and Surveillance of Emerging Arboviruses in the Context of the Circulation of Other Arboviruses. Washington, D.C.: PAHO/WHO; 2024. https://www.paho.org/en/documents/guidelines-detection-and-surveillance-emerging-arboviruses-context-circulation-other